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Background: In patients with highly advanced gastric cancer, the recurrence rate remains high and the prognosis
disappointing. We previously reported a phase I study of a neoadjuvant chemoradiotherapy of S-1 plus weekly
cisplatin. Although adequate safety and efficacy were reported, myelosuppression was frequently observed, leading
to treatment delay in several cases. To decrease toxicity and improve efficacy, we planned a phase I study with a
modified chemotherapy regimen with biweekly cisplatin.
Methods: Patients with advanced gastric cancer and lymph node metastasis who were treated by our institution
between 2011 and 2012 were eligible for inclusion. The initial chemoradiotherapy schedule consisted of 6 weeks of
S-1 orally administered on days 1–15 with an escalating dose of cisplatin administered on days 1 and 15. The
starting dose (level 1) of cisplatin was 15 mg/m2, the second dose (level 2) was 20 mg/m2, and the third dose (level
3) was 25 mg/m2. Radiation of 40 Gy was administered in 20 fractions. After initial chemoradiotherapy, one cycle of
combination chemotherapy with S-1 plus cisplatin was delivered. The second cycle was 42 days in duration and
included S-1 administered on days 1–29 plus biweekly cisplatin administered on days 1, 15, and 29. After
neoadjuvant treatment, a curative gastrectomy with extended (D2) lymph node dissection was planned.
Results: Nine patients were enrolled. At level 3, one patient had dose-limiting grade 3 diarrhea. Another patient
experienced grade 3 nausea and intended to discontinue the treatment. Overall, because 2 of 3 patients
experienced dose-limiting toxicity at level 3, we confirmed level 3 (Cisplatin 25 mg/m2) as the maximum tolerated
dose and level 2 (Cisplatin 20 mg/m2) as the recommended dose (RD). The response rate was 78%, and 8 patients
underwent curative gastrectomy. Resected specimens showed a histological response in 6 patients (75%), including
one with a pathological complete response.
Conclusions: In this phase I trial, RD of cisplatin was identified as 20 mg/m2. Generally, S-1 plus biweekly cisplatin
can be given safely with concurrent radiation. We have initiated a multicenter phase II trial to further confirm the
efficacy and safety of this approach.
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About one million new cases of stomach cancer are esti-
mated to have occurred (988,000 cases), making it cur-
rently the fourth most common malignancy and the
second leading cause of cancer deaths worldwide
(736000 deaths, 9.7% of the total) [1]. At present, for re-
sectable advanced gastric cancer, R0 resection with ex-
tended (D2) lymph node dissection has been shown to
reduce gastric cancer-specific deaths [2,3]. However, in
contrast to the fact that patients at an early stage show a
remarkable 5-year overall survival rate of >90% [4,5], the
locoregional as well as distant recurrence rate is high in
advanced stages such as Stage II and III (based on the
Japanese classification of gastric carcinoma) [6-8]. In
order to achieve further improvements in the prognosis
of advanced gastric cancer, adjuvant chemo- or chemo-
radiotherapy following curative gastric cancer resection
is standard [9-13]. However, in highly advanced gastric
cancers which have bulky primary tumors or multiple
lymph node metastases, the recurrence rate remains
high and the prognosis disappointing [2,6]. Therefore,
there is an urgent need to establish a more intense
multidisciplinary treatment for these patients.
Chemoradiotherapy is reportedly an effective intensive
locoregional treatment for gastric cancer [11-14]. As an ad-
juvant treatment, Lee et al. showed that chemoradiotherapy
led to a statistically significant prolongation of postoperative
disease-free survival in gastric cancer patients with positive
pathologic lymph nodes in the ARTIST trial [15]. There-
fore, chemoradiotherapy could be valuable for these
populations.
Neoadjuvant treatment for advanced gastric cancer pa-
tients was recently shown to be beneficial because of a
higher compliance than adjuvant treatment [16-18]. More-
over, Ajani et al. showed that neoadjuvant chemoradiother-
apy may prolong postoperative survival [19]. However,
there was a limitation to their study as surgery with ex-
tended lymph node dissection was not performed after
treatment. Therefore, we planned neoadjuvant chemoradio-
therapy followed by curative gastrectomy with D2 lymph
node dissection.
We previously conducted chemoradiotherapy with S-1
plus daily cisplatin and concurrent radiotherapy for unre-
sectable or metastatic gastric cancer in the phase II study
and showed its clinical benefit [20]; however, with this treat-
ment schedule, all patients needed to be admitted during
treatment. In order to deliver this treatment in an out-
patient setting, S-1 plus weekly cisplatin with concurrent
radiation was defined as the treatment protocol in our pre-
vious study KOGC01. Although adequate safety and effi-
cacy were reported, myelosuppression was frequently
observed, leading to treatment delay in several cases [21].
In this trial KOGC04, the treatment schedule of cis-
platin was changed from weekly to biweekly because wepreviously showed the maintenance of the efficacy and
safety of the biweekly cisplatin [22]. There was no
change in the schedule of the radiation and its total dose
was the same as that in the KOGC01. The aim of the
present phase I study was to define the maximum toler-
ated dose (MTD) and dose-limiting toxicity (DLT) as
well as the recommended dose (RD) for neoadjuvant
chemoradiotherapy with S-1 plus biweekly cisplatin.
Methods
Study design
This noncomparative, dose-escalation study was con-
ducted at Keio University Hospital, Japan, with the ap-
proval of the Ethics Committee of Keio University
School of Medicine. All eligible patients provided their
written informed consent to participation. The tumors
were classified in accordance with the Japanese Classifi-
cation of Gastric Carcinoma, 3rd English edition (JCGC)
[8]. Clinical adverse events were evaluated according to
the Common Terminology Criteria for Adverse Events
(ver. 4.0). To evaluate treatment response, the Response
Evaluation Criteria in Solid Tumors (RECIST) version
1.1 was used.
Eligibility
All patients diagnosed with advanced gastric cancer at
our institution were eligible for enrollment in this phase
I study. Enrollment criteria were as follows: (1) histo-
logical diagnosis of stomach adenocarcinoma; (2) clinic-
ally measurable lymph node metastasis according to
RECIST (ver. 1.1) criteria; (3) T3 or T4 tumor depth; (4)
neither distant nor peritoneal metastasis identified by
abdominal computed tomography (CT); (5) esophageal
invasion <3 cm; (6) age between 20 and 75 years; (7)
Eastern Cooperative Oncology Group (ECOG) Perform-
ance status of 0 or 1; (8) no past history of chemother-
apy or chemoradiotherapy; (9) no past treatment of
gastric cancer; and (10) adequate organ function (de-
fined by white blood cell count between 3,000 and
12,000 cells/mm3, neutrophil count > 1,500/mm3, plate-
let count > 100,000/mm3, total bilirubin < 1.5 mg/dl,
serum aspartate and alanine transaminase no greater
than 2 times the normal upper limit, and creatinin clear-
ance > 60 ml/min).
Chemoradiotherapy
The chemoradiotherapy protocol consisted of administra-
tion of S-1 plus biweekly cisplatin and radiation (Figure 1).
The initial chemoradiotherapy schedule was for 6 weeks: S-
1 was orally administered every day on days 1–15, and the
total dose was based on the patient’s body surface area
(BSA), as follows: <1.25 m2, 80 mg; 1.25–1.5 m2, 100 mg;
and >1.5 m2, 120 mg. An escalating dose of cisplatin was
administered by infusion over 1 h on days 1 and 15 without
S-1 80 – 120mg/day
1           8          15           22          29 42 1 15                      29                    42
CDDP Day 1 and 15
Radiation 2Gy/Fr, total 40Gy
First course Second course
CDDP Day 1, 15 and 29 
S-1 80 – 120mg/day
Figure 1 Chemoradiotherapy consisted of combination chemotherapy with S-1, biweekly cisplatin, and fractionated radiation therapy.
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was 15 mg/m2, the second dose (level 2) was 20 mg/m2,
and the third dose (level 3) was 25 mg/m2.
Radiotherapy was performed with photons from a lin-
ear accelerator with an energy ≥ 6MV, and three dimen-
sional planning was performed. Dose constraints were as
follows: both kidneys V30 ≤ 20 Gy, liver V30 ≤ 30 Gy,
heart V40 ≤ 30 Gy, both lungs V20 ≤ 20 Gy, spinal cord
maximum dose < 45 Gy. Clinical target volume (CTV)
included the primary tumor with a 3-cm margin and
metastatic lymph nodes with a 1-cm margin. Entire
stomach and the perigastric and celiac lymph node
stations were also delineated as part of the CTV. The
planning target volume (PTV) contained the CTV with
a 2-cm margin to account for setup and organ motion.
To minimize interfraction variation, irradiation was per-
formed in the early morning on an empty stomach. A
total dose of 40 Gy was delivered in 2.0-Gy fractions at a
rate of 5 fractions per week. The dose was prescribed to
a reference point within the PTV according to the Inter-
national Commission on Radiation Units and Measure-
ments 50 and 62.
After initial chemoradiotherapy, one cycle of combin-
ation chemotherapy with S-1 plus biweekly cisplatin was
delivered. This consisted of 42 days of S-1 administered
from day 1 to 28 and of cisplatin administered on days
1, 15, and 29.
In order to maintain adequate renal function, all pa-
tients were recommended oral fluid management with-
out infusional hydration during this treatment same as
that in our previous report [20,22]. Regarding antiemetic
medication, we routinely used 5-HT3 antagonists and
dexamethasone before every cisplatin infusion. Because
cisplatin was delivered fractionally, aprepitant was op-
tional for each case.
DLT and dose escalation method
Patients who experienced any clear treatment-related
grade 4 hematological toxicity, febrile neutropenia
higher than grade 3, or grade 3/4 nonhematological tox-
icity were considered to have experienced DLT. OtherDLT events included a delay in the initiation of the 2nd
cycle of chemotherapy of more than 10 days duration, a
delay of more than 10 days for each cisplatin infusion,
failure to complete radiation within 42 days, and surgery
not performed within 42 days after the completion of
the 2nd cycle of chemotherapy.
Three patients were enrolled at each dose level. If no
DLT was experienced during chemoradiotherapy, an
additional 3 patients were included in the next dose
level. If 1 patient within the first 3 patients recruited to
a level experienced DLT, another 3 patients were treated
with the same dose. If more than 2 out of 6 patients ex-
perienced DLT at a dose, then that dose was defined as
MTD. Furthermore, if 2 or 3 of the first 3 patients re-
cruited to a level experienced DLT, the dose was defined
as the MTD. Therefore, RD was set at one level lower
than MTD.
Clinical evaluation
Between days 29 and 42 of the 2nd cycle of chemother-
apy, an upper gastrointestinal endoscopy and abdominal
CT were performed for clinical evaluation based on
RECIST criteria. Response to neoadjuvant treatment, re-
sectability, and potential for surgical curability were eval-
uated using these assessments.
Surgery
Patients evaluated as being able to achieve curable resec-
tion were eligible for surgery. Surgery was planned
within 6 weeks after the completion of the 2nd cycle.
Gastrectomy with D2 lymph node dissection was per-
formed after we confirmed that there was no peritoneal
metastasis, positive lavage cytology, or adjacent organ in-
vasion. All resected specimens, including the lymph
nodes, were examined to evaluate pathological response
to the preoperative treatment according to the JGCA.
Results
Patient characteristics
Between 2011 and 2012, 9 patients who were diagnosed
with advanced gastric cancer with lymph node metastasis
Table 2 Adverse events
Grade
1 2 3 4 3/4
Hematological
Leukocytopenia Level 1 (n = 3) 1 0 0 0 0
2 (n = 3) 1 0 1 0 1
3 (n = 3) 1 0 0 0 0
Neutropenia 1 0 0 0 0 0
2 0 0 1 0 1
3 1 0 0 0 0
Anemia 1 0 0 0 0 0
2 0 0 1 0 1
3 0 0 0 0 0
Thrombocytopenia 1 1 0 1 0 1
2 2 0 0 0 0
3 0 2 0 0 0
Nonhematological
Nausea 1 0 1 0 0 0
2 0 0 0 0 0
3 1 0 1* 0 1
Diarrhea 1 0 0 0 0 0
2 0 0 0 0 0
3 0 0 1* 0 1
AST/ALT elevation 1 1 0 0 0 0
2 2 0 0 0 0
3 1 0 0 0 0
Bilirubin elevation 1 1 1 0 0 0
2 0 1 0 0 0
3 1 0 0 0 0
Creatinin elevation 1 1 0 0 0 0
2 0 0 0 0 0
3 1 0 0 0 0
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are presented in Table 1. Their median age was 62 years,
and all were male with an ECOG performance status of 0.
Regarding the depth of invasion of the primary tumor, in 6
patients, subserosal invasion (T3) was observed. There was
also one case with invasion of the pancreas, and a gastroje-
junostomy bypass was performed before enrollment. Eight
of 9 patients were diagnosed with N2 lymph node metasta-
sis, and none had suspected distant metastasis. Thus, in
terms of pretreatment staging, 4 of 9 patients were diag-
nosed as Stage IIIA and 5 as stage IIIB.
MTD and RD
Hematological and nonhematological toxicities are
shown in Table 2. No hematological toxicities were
greater than grade 4, which was defined as DLT. Regard-
ing nonhematological toxicities, one patient had dose-
limiting grade 3 diarrhea. In addition, because the oral
intake of a patient was remarkably decreased and the pa-
tient was admitted to the hospital, we evaluated it as
grade 3 anorexia. No significant weight loss was reported
in this case. He intended to discontinue treatment dur-
ing the 1st course. Overall, 2 of 3 patients experienced
DLT at level 3 (Table 3); therefore, level 3 (Cisplatin 25
mg/m2) was set as MTD and level 2 (Cisplatin 20 mg/
m2) as RD.
Clinical Efficacy
Patient outcomes are shown in Table 4. Overall, 7 of 9
patients achieved a clinical partial response (PR), result-
ing in a response rate of 78%. After neoadjuvant therapy,
8 of 9 patients underwent a gastrectomy with D2 (ex-
tended) lymph node dissection. One patient who experi-
enced DLT intended to discontinue treatment during
the 1st course. The median operating time was 249 min,
and the median blood loss was 625 ml. Regarding post-
operative complications, one patient encountered stumpTable 1 Patient and tumor characteristics
n = 9 No. of patients
Age median (range) 62 (52–77)
Sex male/female 9/0
ECOG performance status 0/1 9/0
Location U/M/L 3/2/4





U: Upper-third of stomach; M: Middle-third of stomach; L: Lower-third of stom-
ach; macroscopic type 1: Polypoid tumor; type 2: Ulcerated tumor with sharply
demarcated and raised margins; type 3: Ulcerated tumor with infiltration; type
4: Diffusely infiltrated tumor; SS: Tumor has invaded the subserosa; SE: Tumor
has penetrated the serosa; SI: Tumor has invaded adjacent structures.
*: Dose-limiting toxicity, AST: Aspartate aminotransferase, ALT:
Alanine aminotransferase.leakage due to a pancreatic fistula, and another patient
developed chylous ascites. Both were treated with drain-
age alone, and there were no treatment-related deaths.
Pathological examination of resected specimens showed
that the therapeutic efficacy was histologically classified
as grade 1a in two patients, grade 1b in one patient,Table 3 Dose-limiting toxicity
n = 9 Level 1 Level 2** Level 3*
Hematological toxicity 0 0 0
Nonhematological toxicity 0 0 2
Treatment delay 0 0 0
*: Maximum tolerated dose, **: Recommended dose.
Table 4 Patient outcomes
n = 9 No. of patients
Clinical Response








Operation time (min) 249 (195–288)







PD: Progressive disease; SD: Stable disease; PR: Partial response; CR: Complete
response; Distal: Distal gastrectomy; Total: Total gastrectomy; D1: Limited
lymphadenectomy; D2: Extended lymphadenectomy; R0: No residual tumor;
R1: Microscopic residual tumor; R2: Macroscopic residual tumor.
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8 (75%) patients who underwent surgery showed a histo-
logical response to chemoradiotherapy, including one
patient with a pathological complete response.
Discussion
Intensive multidisciplinary treatment is currently required
for highly advanced gastric cancer, and chemoradiotherapy
is a potent option. In the ARTIST trial, which compared
adjuvant chemoradiotherapy and chemotherapy alone, a
significant reduction in postoperative recurrence was re-
ported in patients who had histologically proven metastatic
lymph nodes [15]. Thus, in this study, efficacy was achieved
among patients with strongly suspected lymph node metas-
tasis preoperatively.
In contrast to the fact that capecitabin was combined
with cisplatin in the ARTIST study, the S-1 was included
in our treatment. The S-1 plus cisplatin treatment
schedule is one of the current standards of care in Japan
for patients with unresectable or recurrent gastric cancer
[23]. Using chemoradiotherapy including S-1, we previ-
ously completed a phase II trial for patients with unre-
sectable or metastatic gastric cancer and showed the
tolerability and efficacy of this treatment schedule [20].
In the ARTIST study, the total cisplatin dose was 60
mg/m2. In this phase I study, although cisplatin was
fractionally delivered, its total dose was the same as that
in the ARTIST study.In general, intensive treatments such as chemoradio-
therapy are believed to weaken the general condition of
patients and increase postoperative complications. In
fact, in our previous study KOGC01, several patients
could not follow the treatment protocol because of
hematological toxicities. In this study, we changed the
chemotherapy schedule for infusional cisplatin from
weekly to biweekly regimen, which was conducted for
unresectable gastric cancer patients and found to be safe
[22]. Consequently, the incidence of grade 3 or 4
hematological toxicity decreased from 40% to 22%, and
8 out of 9 participants could complete the neoadjuvant
chemoradiotherapy regimen. Major toxicities encoun-
tered in the present study were nonhematological toxic-
ities, including nausea and diarrhea, and these could be
managed and were tolerable. Although two patients ex-
perienced postoperative complications, including chyl-
ous ascites and a pancreatic fistula followed by duodenal
stump leakage, they were treated conservatively, which
shows that our regimen is tolerable. Overall, level 3
(Cisplatin 25 mg/m2) was set as MTD and level 2
(Cisplatin 20 mg/m2) as RD.
We previously confirmed a marked response to che-
moradiotherapy and an improved prognosis among pa-
tients with unresectable or metastatic gastric cancer
[20]. Because curative gastrectomy for highly advanced
gastric cancer is invasive, achieving tumor reduction be-
fore surgery can reduce perioperative risks. Thus, our
protocol, which had a high response rate, is favorable as
a neoadjuvant treatment. Although our ability to evalu-
ate efficacy was limited in this phase I trial, we did
achieve a histological response rate of 75%, including
one case with a pathological complete response. There-
fore, the exact treatment efficacy was maintained after
the change of cisplatin schedule from weekly to biweekly
to reduce the toxicities.
As previously reported, chemoradiotherapy was effect-
ive especially for locally advanced gastric cancer
[4,5,15-21]. Particularly, neoadjuvant chemotherapy is
considered to have several clinical benefits such as a re-
duction in the viability of micrometastases, an increase
in the rate of curability, an enhancement in treatment
compliance, and an improvement in the evaluation of
chemosensitivity. Furthermore, the addition of radiation
could improve local control. Therefore, we think that
there were several clinical benefits of neoadjuvant CRT
in patients with advanced gastric cancer, especially in
cases with bulky primary tumor or multiple lymph node
metastases and those patients are preferred participants.
In contrast, patients with scirrhous-type gastric cancer,
which tends to disseminate to the peritoneum, may not
find chemoradiotherapy beneficial.
Nonetheless the recent advancement of technology,
radiotherapy for gastric cancer is still challenging.
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calculation is evolving with three-dimensional conformal
radiotherapy. However, uncertainties arising from varia-
tions in stomach filling and respiratory motion still re-
main [24]. To resolve those issues, in the current study,
appropriate margins were prepared and irradiation was
performed on an empty stomach. Margins must be
modified to maintain dose constraint for the organ at
risk. As a result, we found no enlarged lymph node,
which interfered gastrectomy with extended lymph node
dissection during operation. Notably, surgical complica-
tion considered to possibly be induced by influence of
radiation was not increased. Further advanced treatment
technique such as intensity-modulated radiation therapy
and/or image-guided radiation therapy may allow more
excellent target coverage and normal structure sparing,
and led to superior treatment outcomes [25].
Conclusions
In this phase I study, RD of cisplatin was established as
20 mg/m2, and the efficacy and safety of S-1 plus cis-
platin with concurrent radiation was confirmed for pa-
tients with advanced gastric cancer and lymph node
metastasis. In order to provide further confirmation of
the efficacy and safety of this approach, we have initiated
a multicenter phase II trial.
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